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Abstract
Of the estimated 5.3 million people with Alzheimer’s disease in the United States, more than half would be
classified as having moderate or severe disease. Alzheimer’s disease is a progressive disorder with the moderate to
severe stages generally characterized by significant cognitive, functional, and behavioral dysfunction. Unsurprisingly,
these advanced stages are often the most challenging for both patients and their caregivers/families. Symptomatic
treatments for moderate to severe Alzheimer’s disease are approved in the United States and include the
acetylcholinesterase inhibitor donepezil and the glutamate receptor antagonist memantine. Progressive
symptomatic decline is nevertheless inevitable even with the available therapies, and therefore additional
treatment options are urgently needed for this segment of the Alzheimer’s disease population. An immediate-
release formulation of donepezil has been available at an approved dose of 5-10 mg/d for the past decade.
Recently, the United States Food and Drug Administration approved a higher-dose (23 mg/d) donepezil
formulation, which provides more gradual systemic absorption, a longer time to maximum concentration (8 hours)
versus the immediate-release formulation (3 hours), and higher daily concentrations. Herein, we review (1) the
scientific data on the importance of cholinergic deficits in Alzheimer’s disease treatment strategies, (2) the rationale
for the use of higher-dose acetylcholinesterase inhibitors in patients with advanced disease, and (3) recent clinical
evidence supporting the use of higher-dose donepezil in patients with moderate to severe Alzheimer’s disease.
Background
Alzheimer’s disease (AD) is a progressive disorder that
advances from a period of mild cognitive impairment
through moderate and severe stages. There are currently
an estimated 5.3 million people with AD in the United
States [1], and more than half of these individuals will
likely be categorized as having moderate or severe dis-
ease [2]. These advanced stages of AD extend over a
period of several years and are often the most difficult
for both patients and caregivers [1].
As AD progresses toward the more advanced stages,
symptoms worsen, and the need for effective treatments
grows more critical; yet, clinicians have few options.
Only 2 agents are currently approved in the United Sta-
ted for treatment beyond the mild to moderate stage–
donepezil, an acetylcholinesterase inhibitor (AChEI), and
memantine, a glutamate receptor antagonist that can be
used alone or in combination with an AChEI [3,4]. Pro-
gression of AD is inevitable, however, and cannot be
halted by these therapy options, which address primarily
the disease symptoms. Given the limited choices for
therapy and the often devastating and prolonged impact
of further decline in cognitive and functional abilities,
additional options for treatment are urgently needed for
this segment of the AD population.
In the development of AChEIs, determination of
appropriate dosing was typically based on decisions
regarding a balance of efficacy versus tolerability. For
the past decade, the immediate-release formulation
of donepezil has been used at an approved dose of
* Correspondence: marwan.sabbagh@bannerhealth.com
1The Cleo Roberts Center for Clinical Research, Banner Sun Health Research
Institute, Sun City, Arizona, USA
Full list of author information is available at the end of the article
Sabbagh and Cummings BMC Neurology 2011, 11:21
http://www.biomedcentral.com/1471-2377/11/21
© 2011 Sabbagh and Cummings; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.5-10 mg/d [3]. However, a higher-dose (23 mg/d) done-
pezil formulation was recently approved in the United
States that provides more gradual systemic absorption, a
longer time to maximum concentration (8 hours) com-
pared with the immediate-release formulation (3 hours),
and higher concentrations. In this article we provide
information on the effects of donepezil on the choliner-
gic system and review the scientific and clinical evidence
supporting the use of higher-dose donepezil in patients
with moderate to severe AD.
Importance of cholinergic deficit in the treatment
of AD
An important component of the pathophysiology of AD,
recognized more than 30 years ago, is degeneration of
the cholinergic system [5]. Early histologic studies show-
ing loss of cholinergic activity as AD progresses are sup-
ported by several modern lines of investigation using
advanced imaging techniques, including positron emis-
sion tomography (PET) and magnetic resonance imaging
(MRI). PET imaging has consistently demonstrated
reductions in cortical AChE activity in patients with
mild or moderate AD compared with normal controls
[6-8], and these deficits have been correlated with
increasing cognitive decline [9]. In addition, atrophy of
the nucleus basalis of Meynert, the major source of the
cholinergic neurotransmitter acetylcholine (ACh), its
primary synthesizing enzyme choline acetyltransferase,
and its primary metabolizing enzyme AChE, is notable
in patients with AD on MRI [10,11].
Appreciable loss of cortically projecting cholinergic
neurons occurs as a hallmark of the disease, particularly
in brain areas associated with memory and learning (ie,
the hippocampus, nucleus basalis of Meynert, and cor-
tex) [12,13]. Reduction of cholinergic activity in AD
patients has been observed to correlate with cognitive
deficits as measured by dementia rating scales [14].
The cholinergic abnormalities seen in AD are not
viewed as the cause of the disorder, but cholinergic invol-
vement is significant because it is universal, correlates
with cognitive defects, and is one of the few pathophysio-
logic phenomena that can be addressed with currently
approved treatment options. Enhancement of cognitive
function occurs when the action of ACh is increased via
inhibition of its metabolizing enzymes, principally AChE
[13]. Accordingly, the strategy of increasing cholinergic
activity to mitigate the cognitive symptoms of AD has
been a primary and enduring therapeutic tactic.
Rationale for using higher-dose AChEIs in
patients with moderate to severe AD
Levels of AChE inhibition may be suboptimal
Inhibition of AChE in peripheral red blood cells
(RBCs) has been used as a convenient surrogate
marker for the activity of centrally acting AChEIs [15].
With the use of RBC assays, the level of AChE inhibi-
tion at the highest approved doses of donepezil, rivas-
tigmine, and galantamine has been reported to be
approximately 50% to 80% [16]. These findings led to
the suggestion that current dosing options provide
adequate AChE inhibition.
Functional imaging studies, however, suggest that
RBC-based assays may overestimate AChE inhibition in
the brain [8]. PET imaging studies have shown that
stable regimens of donepezil 5 mg/d or 10 mg/d, or riv-
astigmine 9 mg/d, inhibit in vivo cortical AChE activity
by approximately 20% to 40% in patients with mild to
moderate AD [8,17]. The finding that current dosing
schedules may not achieve the maximum inhibition of
peripheral or central nervous system AChE activity sug-
gests that higher doses of AChEIs may facilitate greater
AChE inhibition and that this may subsequently
increase efficacy [8].
Cholinergic dysfunction is more pronounced in advanced
stages of AD
Data from studies that examined brain tissue samples
obtained during biopsy or autopsy indicate that the cho-
linergic deficit is most evident in patients with more
advanced symptoms [14]. This suggests that the target
level of cholinergic enhancement may change as symp-
toms progress. Patients in early stages of AD may
achieve sufficient cholinergic stimulation from lower
doses of AChEIs, while higher AChEI doses may be
required in patients with more advanced AD.
Utility of higher doses of AChEIs: 5 mg/d versus
10 mg/d donepezil
Clinical trials in which patients with AD were rando-
mized to treatment with donepezil 5 mg/d or 10 mg/d
or placebo have demonstrated a relationship between
benefits in cognition and higher donepezil dose [18,19].
Notably, the benefits of a higher dose of donepezil were
most apparent in trials including patients with more
advanced AD [20].
Results from 3 similarly designed placebo-controlled
clinical trials that assessed the safety and efficacy of
donepezil 5 mg/d and 10 mg/d in patients with mild to
moderate AD (baseline Mini-Mental State Examination
[ M M S E ]s c o r eo f1 0 - 2 6 )w e r ep u b l i s h e di nt h ep e r i o d
after the initial US Food and Drug Administration
(FDA) approval of donepezil in 1996. In each trial,
co-primary outcomes were the Alzheimer’s Disease
Assessment Scale-cognitive subscale (ADAS-cog) and
the Clinician’s Interview-Based Impression of Change-
plus caregiver input (CIBIC-plus, a measure of global
function) [21-23]. Subjects were treated for either
12 weeks [22] or 24 weeks [21,23].
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cebo were seen in both co-primary variables at study
end point with donepezil 5 mg and 10 mg. The magni-
tude of benefit was numerically greater with donepezil
10 mg compared with 5 mg across the 3 studies, but
either between-dose differences were not statistically sig-
nificant [22] or statistical comparisons were not
reported [21,23]. More recently, however, a meta-analy-
sis of 10 randomized, double-blind, placebo-controlled
donepezil studies involving 2376 patients, which
included the aforementioned 3 studies, found that
improvements in ADAS-cog at 18 and 24 weeks were
significantly greater with donepezil 10 mg compared
with donepezil 5 mg (p = 0.015 and p = 0.005, respec-
tively) [19]. The meta-analysis also reported an increase
in cholinergic adverse events (AEs) when the dose was
increased from 5 mg/d to 10 mg/d. However, this
increase was generally attributed to the outdated prac-
tice of increasing the donepezil dose after just 1 week of
treatment, and the authors concluded that both doses
were well tolerated in this study population.
Results from a recent study published by Nozawa et al
[20] suggest that increasing the dose of donepezil may
be beneficial to patients with more advanced AD symp-
toms. In this open-label study, patients categorized with
mild, moderate, or advanced AD (based on a Clinical
Dementia Rating scale score of 1, 2, and 3, respectively)
who had been on a stable regimen of donepezil 5 mg/d
were increased to donepezil 10 mg/d. Patients with mild
or moderate AD demonstrated no significant decline in
MMSE or Revised Hasegawa Dementia Scale (HDS-R)
scores during the 6 months before or after donepezil
was increased from 5 mg/d to 10 mg/d. However, in the
more advanced AD group, which had a mean baseline
MMSE of 12.7, MMSE and HDS-R scores had decreased
significantly during the 6 months prior to dose increase
but no additional declines were observed in the 6 months
following dose increase. During this study, 7 of 61
patients (11.5%) withdrew due to AEs that emerged
after their dose was increased from 5 mg/d to 10 mg/d;
however, all AEs appeared in these patients within
1 month of the dose increase and symptoms rapidly
improved after dose modification back to 5 mg/d [20].
Outcomes from a donepezil dose-ranging clinical trial
also suggest that higher doses of donepezil are more
effective and similarly well tolerated in patients with
advanced AD [18]. In this blinded study, patients with a
baseline MMSE score of 1 to 12 were treated for
24 weeks with donepezil 10 mg/d, donepezil 5 mg/d, or
placebo. Among the study population, mean baseline
scores on the Severe Impairment Battery (SIB), a scale
designed specifically to assess cognition in patients with
more severe cognitive dysfunction, ranged from 56.7 to
67.0 across the 3 treatment groups. Co-primary end
points were CIBIC-plus and SIB. At study end point,
mean SIB scores with donepezil 10 mg/d and donepezil
5 mg/d had improved (+4.7 points and +2.5 points,
respectively), whereas the mean score in the placebo
group had declined by 4.2 points; differences between
mean SIB scores for both donepezil doses and for the
placebo group were statistically significant. On the
CIBIC-plus, donepezil 10 mg/d resulted in significant
benefits over placebo, but no significant benefits over
placebo were seen with the 5 mg/d dose. Notably, a sig-
nificant dose-response relationship was demonstrated on
both the SIB and the CIBIC-plus (p ≤ 0.003), suggesting
that patients with advanced AD are most likely to
receive benefit from higher levels of AChE inhibition.
As seen in the mild to moderate AD population, an
increased incidence of treatment-emergent AEs (TEAEs)
was observed in the donepezil 10 mg/d group (83.3%)
versus the donepezil 5 mg/d group (78.2%) in this study.
However, this difference was not statistically significant
and the higher dose was seen to be safe and well toler-
ated in patients with advanced AD [18].
Investigation of doses of donepezil in excess of
10 mg/d
Data showing improved results with 10 mg/d versus
5 mg/d donepezil, along with findings suggesting that
patients in more advanced stages of AD show a more
pronounced effect with higher dosing, led to trials test-
ing doses higher than 10 mg/d [24,25]. In a 24-week
pilot study (N = 31) designed to assess the safety and
tolerability of higher than standard doses of donepezil in
patients with mild to moderate AD (MMSE score,
10-26) on a stable 10 mg/d donepezil regimen, once-daily
administration of up to 20 mg was found to be safe and
well tolerated. No differences in efficacy outcomes were
reported; this study was not powered to show statistical
differences between groups on clinical outcomes [24].
To test the hypothesis that patients with more
advanced AD can benefit from an increased dose of
established AChEI therapy, a study was designed to
evaluate the safety and efficacy of a donepezil 23 mg
tablet. This new donepezil formulation was developed to
p r o v i d eah i g h e rd o s ea d m i n i s t e r e do n c ed a i l ya n dt o
avoid sharp increases in peak concentration.
Results of this phase 3 trial to assess the safety and
efficacy of the 23 mg/d donepezil tablet have recently
been published [25], and this treatment has been subse-
quently approved by the FDA for use in patients with
moderate to severe AD. In this 24-week randomized,
double-blind, global, head-to-head clinical trial, more
than 1400 patients with moderate to severe AD (MMSE,
0-20) on a stable donepezil 10 mg/d regimen for ≥ 3
months were randomized to increase their dosages to
the once-daily donepezil 23 mg tablet or to be
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points were changes in SIB score and the CIBIC-plus
overall change score at Week 24. Patients in the donepezil
23 mg group showed a statistically significant improve-
ment in cognition as measured by the SIB compared with
donepezil 10 mg (Figure 1A). The least squares (LS) mean
difference between treatments for the change from base-
line to Week 24 for the 23 mg and 10 mg groups was
2.2 points (p < 0.001). Among the total study population
(MMSE, 0-20), significant incremental benefit on the
CIBIC-plus was not seen with donepezil 23 mg/d versus
donepezil 10 mg/d over 24 weeks of treatment.
In a post hoc analysis of patients with more severe
cognitive impairment (baseline MMSE, 0-16), significant
differences favoring donepezil 23 mg/d were demon-
strated on both the SIB (Figure 1B) and the CIBIC-plus.
In this subpopulation, representing 70% of patients in
the study, the LS mean between-treatment difference in
change in SIB score was 3.1 points (p < 0.0001) at
Week 24. CIBIC-plus scores at Week 24 were 4.31
and 4.42 in the 23 mg and 10 mg groups, respectively
(p = 0.0279).
During the study, TEAEs were reported in more
patients receiving donepezil 23 mg/d (73.7%) than
receiving donepezil 10 mg/d (63.7%) [25]. The most
common TEAEs considered probably related to treat-
ment with donepezil 23 mg/d and 10 mg/d were nausea
(6.1% vs 1.9%), vomiting (5.0% vs 0.8%), and diarrhea
(3.2% vs 1.5%). In the 23 mg/d group, gastrointestinal
AEs occurred most frequently during the first month of
treatment, but were relatively infrequent beyond this
time. Serious TEAEs were noted in a similar proportion
of patients in the 23 mg/d and 10 mg/d groups (8.3% vs
9.6%), with the majority in both groups considered
unrelated to treatment. Overall, 18.6% of patients trea-
ted with donepezil 23 mg discontinued due to TEAEs,
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Figure 1 LS mean SIB total score change from baseline by Visit (observed cases) and at primary end point (Week 24-LOCF) in patients
with MMSE scores of 0-20 (primary analysis; A) and 0-16 (post hoc analysis; B).
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majority (>60%) of discontinuations from the 23 mg
group occurred in the first month of therapy.
This 24-week study demonstrated that treatment with
donepezil 23 mg tablets can provide additional cognitive
benefit in patients with moderate to severe AD com-
pared with 10 mg donepezil, and its findings are consis-
tent with previous analyses showing greater benefit with
10 mg than with 5 mg [18-20]. Although TEAEs were
more commonly observed upon initiation of the 23 mg/d
dose, as was expected based on prior experience of dose
increases from 5 mg/d to 10 mg/d, the higher dose was
generally well tolerated, with a safety profile typical of
AChEIs. Moreover, strategies required to manage AEs
emerging upon a dose increase to 23 mg/d should be
familiar to health care providers already treating patients
with standard donepezil regimens. Overall, although
further investigations are needed to determine the long-
term benefits provided by donepezil 23 mg, the results
described by Farlow and colleagues [25] offer evidence
that the use of higher doses of AChEIs may be a worth-
while goal to improve treatment of AD in patients with
more advanced disease.
Conclusions
Evidence indicates that cholinergic deficits correlate with
the cognitive defects of AD. As AD symptoms increase
in severity over time, there are progressive declines in
markers of cholinergic activity. Inhibition of AChE
increases cholinergic function, which is theorized to
result in dose-dependent improvements in cognition.
Patients with AD continue to decline even when trea-
ted with the highest currently approved doses of AChEIs,
and patients with advanced disease demonstrate the most
profound impairment in cholinergic function. Imaging
studies have demonstrated that, with the currently used
doses of AChEIs, inhibition of brain AChE is suboptimal.
Data from a recently published 24-week clinical trial in
patients with moderate to severe AD demonstrate that
treatment with a 23 mg formulation of donepezil results
in significant benefits in cognition compared with stan-
dard doses, with an acceptable tolerability profile that is
consistent with the AChEI class. Donepezil 23 mg did
not differ from the 10 mg dose in terms of the incidence
of serious side effects and differences in discontinuation
rates between the two doses were not evident after the
first month of treatment. Once-daily donepezil 23 mg,
therefore, represents an additional treatment choice for
patients with advanced AD.
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